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ABSTRACT:   Aim of the study: The aim of this study was to evaluate the influence of laparoscopic sleeve gastrectomy and laparo-
scopic Roux-en-Y gastric by-pass on risk factors of cardiovascular diseases.
  Material and methods: We analyzed prospectively collected data of patients operated for morbid obesity who were 
qualified for laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric by-pass (LRYGB). Risk factors for 
cardiovascular diseases were assessed with the SCORE scale and both full and hard Framingham cardiovascular risk 
scores (FCRs). The data were collected on admission and one year after the procedures. We enrolled 264 patients (119 
females, 116 males, 40.2±9.9 years old), of whom 117 underwent LRYGB and 118 LSG, respectively.
  Results: Preoperatively, 12% of patients were in the high-risk category of the SCORE scale, 65% were in the moder-
ate risk category, and 24% were in the low-risk category. The median score of the SCORE scale was 1 (1-2). Lipid-based 
full FCR was 34.5% (24%-68%) and the hard FCR was 17.5% (10%-52%), while the respective BMI-based FCRs were 
59% (31%-84%) and 37% (15%-67%). One year after the procedures, the mean %EBMIL (62.88%±20.02%) and %EWL 
(53.18%±15.87) were comparable between both procedures. Hypertension treatment was not necessary in 33 patients 
after LSG and in 55 after LRYGB. Diabetes mellitus remitted in 9 and 29 patients, respectively. Both procedures signifi-
cantly reduced high and moderate risk prevalence in the SCORE scale in favor of the low risk category. Surgical inter-
ventions resulted in significant reductions of FCRs 1 year after surgery ( p<0.001). 
  Conclusions: Both LSG and LRYGB lead to a significant and comparable body mass reduction. Both procedures signifi-
cantly decrease of the risk of cardiovascular diseases, based on SCORE and Framingham scales.
KEYWORDS:   morbid obesity, bariatric surgery, laparoscopic sleeve gastrectomy, laparoscopic Roux-en-Y Gastric Bypass cardiovas-
cular risk factors, SCORE, Framingham 
INTRODUCTION
Currently, the  prevalence of overweight or obesity in Europe 
ranges between 40-50%, while in the US it reaches 67% [1]. 
Increased body weight causes numerous comorbidities in-
cluding cardiovascular diseases (CVD), hypertension, dys-
lipidemia, and type 2 diabetes mellitus. Obesity is associated 
with increased cardiovascular (CV) morbidity and mortality 
[2]. The risk of coronary heart disease is three times greater 
in obese patients compared with people with normal BMI 
[3, 4]. According to WHO, in 2015, CVDs were the main 
cause of mortality worldwide. Approximately 17.5 million 
people died from CVDs in 2012, which represents almost 
30% of all global deaths. In Poland, in 2010, 456 deaths per 
100,000 people were due to CVDs, representing 45% of all 
mortality causes, while in the US, in 2007, this figure ex-
ceeded 30% [5].
Conservative methods of treating obesity do not reduce the oc-
currence of CV events [6, 7]. Bariatric surgery is superior to con-
ventional weight loss therapy, resulting in a long-term reduction 
of BMI and amelioration of metabolic and functional CVD risk 
factors in morbidly obese people [8]. The prevalence of obesi-
ty-related comorbidities decreases with the reduction of BMI. 
Such positive effects include improved insulin resistance and li-
pid metabolism, reduction of hypertension, amelioration of en-
dothelial dysfunction and inflammation, reduction of ventricular 
hypertrophy and sympathetic overactivity [2].
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AIM OF THE STUDY
The aim of this study was to evaluate the influence of laparo-
scopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric 
by-pass on risk factors of cardiovascular diseases.
METHOD
Prospectively collected data of patients operated for morbid obesi-
ty in the 2nd Department of Surgery, JUMC were analyzed. Guide-
lines of the Metabolic and Bariatric Surgery Section of the Polish 
Surgical Society were used as criteria for surgical treatment, i.e., 
body mass index (BMI) ≥ 35 kg/m2 with obesity comorbidities, 
or BMI ≥ 40 kg/m2 with or without comorbidities [9, 10]. Patients 
were assessed preoperatively and allocated to laparoscopic sleeve 
gastrectomy (LSG) and laparoscopic Roux-en-Y gastric by-pass 
(LRYGB). In the absence of uniform recommendations for qualifi-
cation to individual bariatric procedures, the choice of procedure 
was influenced by the expected impact on improvement in met-
abolic control or remission of diabetes, degree of excess weight 
loss and its sustainability. In selecting the method of treatment, 
we took into account the experience of our center (LSG, LRYGB), 
patients’ BMI, age, patients’ condition, obesity-related co-morbid-
ities (especially type 2 diabetes), changes in the anatomy of the di-
gestive tract due to disease or previous surgery (e.g. hiatal hernia, 
resections of the stomach, intestines), eating habits, expectations, 
patients’ preferences, and patients’ compliance in the periopera-
tive period and during long-term care[9-12].
The study was designed to assess the influence of laparoscopic 
sleeve gastrectomy and laparoscopic Roux-en-Y gastric by-pass 
on risk factors of cardiovascular diseases, using the SCORE scale 
and Framingham cardiovascular risk score (FCRs), both assessed 
preoperatively and 12 months after surgery.The SCORE scale (sys-
temic coronary risk evaluation) designed for the European popu-
lation classifies patients into 3 risk groups (low, moderate, high), 
using the following parameters: age, gender, systolic blood pres-
sure (at first ambulatory visit), total cholesterol level, and tobac-
co smoking. The SCORE calculator, compatible with the guide-
lines of the European Society of Cardiology guidelines, was used 
to calculate risk scores for all patients with the same parameters 
before and after surgery. 
The 30-year risk score for cardiovascular disease was calculated 
using Framingham risk score for prediction of cardiovascular dis-
eases, both BMI-associated and blood lipids-associated scales were 
used. The Framingham scale enables to calculate the risk of hard 
cardiovascular diseases and the full risk of cardiovascular diseases. 
Hard CVDs include coronary death, myocardial infarction, and 
fatal or non-fatal stroke. The full CVDs include both hard CVDs 
and other CVDs such as coronary insufficiency, angina pectoris, 
transient ischemic attack, intermittent claudication, and conges-
tive heart failure. For calculation of BMI-associated hard and full 
CVD risks, we used the following qualitative and quantitative data: 
gender, age, systolic blood pressure, tobacco smoking, treatment 
of hypertension, BMI, and presence of diabetes mellitus. For cal-
culation of lipid-based hard and full CVD risks we used gender, 
age, systolic blood pressure, total cholesterol serum level, HDL 
serum level, tobacco smoking, treatment of hypertension, and 
presence diabetes mellitus. 
The data were collected on admission and during follow-up vis-
its that took place one year after surgery. Height and weight were 
measured according to a standard protocol, and the body mass 
index was calculated. Systolic blood pressure was measured 
by professional personnel according to a standard protocol for 
obese patients. Fasting blood specimens, total cholesterol (TCL), 
high-density lipoproteins (HDL), and low-density lipoproteins 
levels (LDL) were measured using standardized methods. Dur-
ing follow-up visits (12 months after surgery), bariatric treatment 
effects were measured. The parameters evaluated preoperative-
ly and on follow-up were used for calculation of percentage of 
excess BMI loss (%EBMIL) and percentage of excess weight loss 
(%EWL), in accordance with standard guidelines. 
Statistical analysis was performed using STATISTICA 10.0 PL. 
The data are presented as median values with inter-quartile rang-
es. The chi-squared exact Fisher test, Pearson and Yates tests were 
used to compare qualitative data. The t-test and Mann-Whitney, 
Wilcoxon, and Cochrane-Cox tests analyzed quantitative differ-
ences between the groups. Statistical significance was accepted 
with p-values of 0.05.
ETHICS
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the in-
stitutional and national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable 
ethical standards. The study was approved by the Bioethics 
Committee of the Jagiellonian University (KBET/156/B/2011).
All patients included in the study gave written consent for par-
ticipation in the study after being thoroughly informed on as-
sumptions and aims of the study.
MATERIAL
Out of 268 patients who underwent laparoscopic bariatric pro-
cedures in the 2nd Department of General Surgery CM UJ in 
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2015 between January and May, 264 were enrolled in the study 
(119 females, 116 males, 40.2±9.9 years). Of those, 117 (49%) 
patients underwent LRYGB (58 females, 59 males, 39.3±10.6 
years on average), and 118 (51%) patients underwent LSG (61 
females, 57 males, 41.1±9.3 years on average), respectively. Ta-
ble 1 presents LRYGB and LSG group characteristics. Figure 1 
illustrates the flow of patients through the study. 
RESULTS
Patients with type 2 diabetes mellitus were excluded from the 
SCORE analysis. According to the SCORE scale, preoperative-
ly, 12% of patients were in the high cardiovascular risk catego-
ry, 65% were at moderate risk, while 24% were at low risk. The 
median score was 1 (1-2) (Fig. 2 and 3).
Based on the lipid-related Framingham cardiovascular risk cal-
culator, the median preoperative risk of hard CVD or coronary 
insufficiency, angina pectoris, transient ischemic attack, inter-
mittent claudication, or congestive heart failure was 34.5% (24%-
68%) in the entire study sample, while the median risk of cor-
onary death, myocardial infarction, or fatal or non-fatal stroke 
was 17.5% (10%-52%). While using the BMI-related Framing-
ham cardiovascular risk calculator, the preoperative median risks 
were 59% (31%-84%) and 37% (15%-67%), respectively (Tab. 2).
Preoperatively, type 2 diabetes mellitus and hypertension were 
common, more commonly present in the LRYGB group. Patients 
with hypertension treatment were more likely to be qualified 
for the LRYGB procedure. The prevalence of smoking was low. 
In the group of patients qualified for LSG, 6 (5%) patients had 
not quit smoking preoperatively and had still smoked tobacco 
1 year after the procedure. The same was observed in 14 (12%) 
patients qualified for LRYGB, where all 14 patients still smoked 
after one year. Median total cholesterol levels were not elevated 
prior to surgery; however, non-optimal levels were often pres-
ent, and while analyzing cholesterol fractions, dyslipidemia was 
commonly present (Tab. 3) . 
One year after the procedures, the effects of bariatric treatment 
were assessed. The mean %EBMIL was 62.88%±20.02% in the 
Fig. 1. Flow-chart.
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an important cause of CVDs, and it can intensify certain CVD 
risk factors, for instance, dyslipidemia, hypertension, or diabe-
tes mellitus [5, 14]. 
It has been proven by randomized clinical trials and meta-anal-
yses that surgical intervention leads to a substantial reduction of 
weight and improvements in comorbidities, both of which are 
maintained for a long time [15-21]. The reduction of CV diseases 
is achieved due to the pleiotropic effects of BMI decrease after 
surgery, which include improvement in such comorbidities as 
systemic hypertension, dyslipidemia, diabetes mellitus, cardiovas-
cular dysfunction, liver disease, and obstructive sleep apnea [2]. 
According to the review by Benraoune and Litwin, a significant 
reduction of systolic blood pressure resulting from bariatric 
procedures ranges from 4mmHg to 15mmHg after 1-2 years. 
A complete resolution of hypertension (normal blood pressure 
entire study sample, and it was comparable in patients who un-
derwent LSG  and LRYGB (65.5%±21.34% vs. 60.26%±18.88%, 
p=0.045). The mean %EWL was 53.18%±15.87 in all pa-
tients, and it was also comparable after both procedures (LSG 
54.01%±16.79% vs. LRYGB 52.36%±15.36%, p=0.77). 
One year after surgery, the treatment of hypertension was not 
necessary in 33 patients in the LSG group and in 55 patients 
in the LRYGB group, while remission of diabetes mellitus was 
observed in 9 and 29 patients, respectively. There were no sig-
nificant changes in total cholesterol levels in both groups (LSG 
p=0.263, LRYGB p=0.379). The average HDL level increased sig-
nificantly in both groups (LSG p=0.001, LRYGB p=0.001). The 
median LDL level did not change significantly in the examined 
time period in both groups (LSG p=0.552, LRYGB p=0.394). The 
median triglyceride levels decreased significantly one year af-
ter LSG and LRYGB (p=0.003 and 0.001, respectively) (Tab. 3).
Both procedures significantly reduced high and moderate SCORE 
risk in favor of the low risk (Fig. 2). Most of LRYGB patients had 
a preoperative moderate SCORE cardiovascular risk, and this 
was similar 1 year after the procedure (Fig. 3.). The efficacy of 
lowering moderate risk after one year was similar in patients 
undergoing the LSG procedure, and high SCORE risk in all 
LRYGB patients was reduced. The risk of patients who under-
went LSG resembled the normal distribution, and a decrease of 
high and moderate SCORE risks was observed as in the case of 
the whole study sample. 
In the analysis of the SCORE scale in both groups, we excluded 8 
patients with a preoperative SCORE risk of zero. The median risk 
reduction on the SCORE scale was 1 point (0.5, 1;  p<0.001). The 
medians of reductions in risk scores did not differ between the 
procedures (p=0.24) and were the same as in the entire sample. 
In all cases and both groups, surgical intervention resulted in 
a significant reduction of lipid- and BMI-related  Framingham 
cardiovascular risks scores 1 year after the procedures (p<0.001). 
Statistical analysis showed significant differences between LSG 
and LRYGB in favor of a greater reduction following LRYGB; 
however, prior to the procedure, higher Framingham cardiovas-
cular risks were found in patients undergoing LRYGB, which 
definitely contributed to a greater risk reduction (Tab. 2).
DISCUSSION
Morbid obesity is a disease that affects an increasing number 
of people, and it indisputably requires intervention. This is re-
flected by an increasing trend in the total number of bariatric 
procedures and bariatric surgeons in Poland [13]. Obesity is 
Fig. 2. SCORE risk categories preoperatively and one year after procedures.
Fig. 3.  SCORE risk categories preoperatively and one year after procedures in 
patients undergoing LSG and LRYGB.
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 In our study, we noted similar results, since hypertension re-
solved in 56% of patients after LSG and in 57% of patients after 
LRYGB (overall, 57% of subjects with preoperative hyperten-
sion experienced resolution of the disease following surgery). 
Improvements in the lipid profile were noted in both groups. 
In the LSG group, 75% of patients suffering from diabetes pre-
operatively did not need any medication one year later, and this 
was also observed in 90% of patients in the LRYGB group (86% 
of all participants). Bariatric surgery dramatically improves di-
abetes and insulin resistance. These changes occur within days 
after the procedure and therefore the enhanced glycemic reg-
ulation cannot be explained by weight loss [24]. Such findings 
are considered as evidence that surgical treatment, particularly 
gastric bypass or the sleeve procedure, provoke modifications 
without drug use) occurs in 20%-40% of patients  2 years after 
bariatric surgery [21, 22]. In the Swedish Obesity Study (SOS 
study), the most pronounced effect on blood pressure was noted 
on the 2-year follow-up; however, this improvement was lost on 
the 10-year follow-up [21] . The improvement of dyslipidemia 
is frequently comparable or even larger than fallowing pharma-
cological treatment. LDL cholesterol levels decline (−5 to −40 
mg/dl), triglycerides also noticeably decrease (−50 to −100 mg/
dl), whereas HDL cholesterol levels typically increase (+5 to + 
15 mg/dl).  Up to 80% of patients suffering from type 2 diabetes 
mellitus demonstrate a complete resolution of the disease after 
1-2 years (normal fasting glucose without drug use) [21, 23]. 
On the 10-year follow-up, 36% of those patients continued to 
be free from diabetes [21].
Tab. I. Characteristics of patients
 PROCEDURE
LSG LRYGB P-VALUE
Age years, mean±SD 39.33±10.56 41.12±9.29 0.600
Sex no., total % 57 M (39%). 
61 F (71%)
59 M (53%). 
58 F (47%)
0.510
Height m, mean±SD 1.71±0.09 1.74±0.09 0.340
Preoperative BMI                kg/m2, mean±SD 44.74±4.52 50.43±6.40 0.004
Preoperative weight kg, mean±SD 132.14±21.96 154.16±27.76 0.013
Tobacco smoking no., total % 6 (5%) 14 (12%) 0.957
Hypertension treatment no., total % 59 (50%) 96 (82%) 0.097
Diabetes mellitus no., total % 13 (11%) 33 (29%) 0.063
Tab. II. Median CV risks (IQR) according to Framingham CV risk calculator
OVERALL LSG LRYGB P-VALUE OF GROUPS’ RISK 
REDUCTION DIFFERENCES
Lipid-based full Framingham CV risk
preoperative 34.5% (24-68) 25% (11-58) 43% (33-69) 0.001
1 year after 15.5% (9-27) 12% (7-42) 18% (12-24)
P-value of repeated measures <0.001 <0.001 <0.001
Lipid-based hard Framingham CV risk
preoperative 17.5% (10-52) 12% (4-52) 22% (14-52) 0.017
1 year after 8% (4-16) 6% (3-23) 9% (6-13)
P-value of repeated measures <0.001 <0.001 <0.001
BMI-based full Framingham CV risk
preoperative 59% (31-84) 33% (19-82) 71% (59-84) <0.001
1 year after 23.5% (11-57) 16% (9-57) 29% (20-53)
P-value of repeated measures <0.001 <0.001 <0.001
BMI-based hard Framingham CV risk
preoperative 37% (15-67) 18% (8-67) 53% (37-66) 0.002
1 year after 14% (5-32) 8% (4-32) 18% (10-28)
P-value of repeated measures <0.001 <0.001 <0.001
WWW.PPCH.PL46
 original article
We proved that both procedures significantly reduced high and 
moderate SCORE risk in favor of the low risk; however, patients 
with type 2 diabetes mellitus  were excluded from the SCORE anal-
ysis, because this scale is not recommended for cardiovascular risk 
assessment in patients with this comorbidity. Patients with type 
2 diabetes mellitus are already at a higher risk than indicated by 
the SCORE scale. We chose the Framingham cardiovascular risk 
scores (FCRs) to estimate the 30-year CVD risk change in all in-
dividuals, and we revealed a relative risk reduction by more than 
a half (50-66%, depending on the used model, lipid or BMI, and 
type of surgery). The lipid model of FCRs seems to be the most 
adequate for this research, as it was not influenced by weight and 
because it is the optimal model to evaluate the significance of bar-
iatric surgery in the CVD risk improvement [2]. The relative im-
provement of 58% was observed following LRYGB, considering all 
CV events (full FCRs), and we observed an improvement of 59% 
in the gut-secreted hormones that sharply regulate metabolism 
[24]. Despite the lack of smoking cessation in 20 patients, we de-
cided not to exclude them from the analysis; however, this could 
slightly increase the risk for cardiovascular events.  Recent pro-
spective, case-control, population studies have also reported sur-
gical treatment to prolong life expectancy in the morbidly obese. 
Adams et al. reported that bariatric surgery was responsible for 
a 56% reduction in mortality caused by coronary heart disease 
and a 40% decrease in all cause fatality (retrospective cohort 
study, 7.1 years of follow-up) [25]. Christou et al. demonstrat-
ed that LRYGB was associated with an 82% risk reduction for 
cardiovascular morbidity and an 89% risk reduction for overall 
mortality (5 years follow-up) [26]. The results of the SOS study 
supported this finding by demonstrating a reduction of both fa-
tal and total cardiovascular events, by 53% and 33%, in a group 
of patients after surgery compared to controls, respectively [27].
Tab. III. Patients’ clinical characteristics
PROCEDURE LSG LRYGB P-VALUE
Systolic blood pressure mmHg,  median
preoperative 120 160 0.023
1 year after procedure 120 120 0.410
Total cholesterol level mg/dl, mean±SD
preoperative 186.07±38.84 159.23±29.14 0.030
1 year after procedure 195.71±33.27 146.70±21.11 0.0004
HDL level mg/dl, mean±SD
preoperative 41.83±10.98 38.03±9.89 0.297
1 year after procedure 66.42±16.44 53.00±11.07 0.009
LDL level mg/dl, mean±SD
preoperative 116.46±27.71 90.08±25.64 0.007
1 year after procedure 111.69±36.20 82.80±30.60 0.017
TGC mg/dl, median (quartiles)
preoperative 132.75 (83.19-156.65) 141.60 (111.51- 194.70) 0.361
1 year after procedure 82.31 (61.95-133.64) 82.31 (64.61-108.86) 0.520
Tobacco smoking no., total %
preoperative 6 (5%) 14 (12%) 0.957
1 year after procedure 6 (5%) 14 (12%) 0.957
Hypertension treatment no., total %
preoperative 59 (50%) 96 (82%) 0.097
1 year after procedure 26 (22%) 41 (35%) 0.63
Diabetes mellitus no., total %
preoperative 13 (11%) 33 (29%) 0.063
1 year after procedure 3 (3%) 3 (3%) 0.492
MPV fL, mean±SD
preoperative 10.80±0.92 10.86±0.95 0.854
1 year after procedure 10.62±0.97 11.16±1.16 0.156
1 year after procedure BMI                kg/m2, mean±SD 31.93±4.50 35.96±6.69 0.047
1 year after procedure weight kg, mean±SD 93.31±18.41 110.23±26.80 0.041
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Society and the Polish Society for Atherosclerosis Research 
allow the use of the Framingham model due to its simplici-
ty and reliability in everyday medical practice [31, 32]. The 
evaluation of the risk of CVD using this scale may be part of 
routine diagnosis and a reference point, when deciding on 
medications and the type and aggressiveness of interventions 
for prevention of CVD.
Based on our study, both methods, i.e., laparoscopic Roux-en-Y 
gastric bypass and laparoscopic sleeve gastrectomy, lead to a sig-
nificant and comparable body mass reduction and a significant 
decrease of the risk of CVD. It seems that prevention of CVDs 
due to surgical treatment is more strongly associated with the 
initial status of patients than the type of surgery. Moreover, the 
almost universal improvement in CVD risk, independent of 
baseline BMI or surgery method, suggests that bariatric sur-
gery may be a reasonable solution to reduce CVD risk in indi-
viduals with primary BMI below the prevailing standards. Large 
prospective studies are needed to assess this issue in morbidly 
obese patients [2]. 
CONCLUSION 
Both laparoscopic sleeve gastrectomy and laparoscopic Roux-
en-Y gastric bypass lead to a significant and comparable body 
mass reduction, and they both significantly decrease the risk 
of cardiovascular diseases, based on the SCORE scale and 
Framingham scores.
of fatal CV events incidence (hard FCRs). For LSG, these figures 
were 52% and 50% respectively. In the BMI model, we observed an 
improvement of 59% (full FCRs) and 66% (hard FCRs for LRYGB); 
the respective values for the LSG group were51% and55%.
Several groups have estimated the alterations in long-term risk 
of CV events due to beneficial effects of surgical treatment on 
cardiac risk factors. Based on Framingham risk scores, Vogel 
et al. assessed  that the 10 year-risk would decrease from 6% at 
baseline to 3% following LRYGB [28]. Batsis et al. showed that 
LRYGB reduced the prevalence of CV events relatively by 51% 
(from 37% to 18%) and the  prevalence of cardiovascular death 
by 55% (from 5.8% to 2.6%) [29]. 
Gastric by-pass is more frequently studied, while there are lim-
ited data showing the influence of other bariatric procedures 
on FCRs. The study by Largent et al. analyzed patients after the 
laparoscopic adjustable gastric banding procedure, showing a 
reduction of estimated risk for CVD by 33% [30]. This study re-
vealed a slight predominance of LRYGB over LSG in reducing 
the CVD risk. However, this can be due to a limited number 
of participants and differences in patients’ characteristics be-
tween the groups. 
A limitation of this study is the use of the Framingham CVD 
risk scale in the Polish population. The authors of the Fram-
ingham CVD risk assessment model suggest to limit its ap-
plication only to the population of African-Americans and 
Americans of European descent. However, the Polish Cardiac 
REFERENCES
1. Nguyen, D.M. and H.B. El-Serag, The epidemiology of obesity. Gastroenterol 
Clin North Am, 2010. 39(1): p. 1-7.
2. Boido, A., et al., Bariatric surgery and prevention of cardiovascular events and 
mortality in morbid obesity: mechanisms of action and choice of surgery. Nutr 
Metab Cardiovasc Dis, 2015. 25(5): p. 437-43.
3. Calle, E.E., et al., Body-mass index and mortality in a prospective cohort of 
U.S. adults. N Engl J Med, 1999. 341(15): p. 1097-105.
4. Tavani, A., et al., Body weight and risk of nonfatal acute myocardial infarc-
tion among women: a case-control study from northern Italy. Prev Med, 1997. 
26(4): p. 550-5.
5. Roger, V.L., et al., Heart disease and stroke statistics--2011 update: a 
report from the American Heart Association. Circulation, 2011. 123(4): 
p. e18-e209.
6. Al-Habbal, Y., C. Christophi, and V. Muralidharan, Aneurysms of the splenic 
artery - a review. Surgeon, 2010. 8(4): p. 223-31.
7. Trastek, V.F., et al., Splenic artery aneurysms. Surgery, 1982. 91(6): p. 694-9.
8. Ikeda, O., et al., Nonoperative management of unruptured visceral artery 
aneurysms: treatment by transcatheter coil embolization. J Vasc Surg, 2008. 
47(6): p. 1212-9.
9. Wyleżoł, M., et al., Polskie rekomendacje w zakresie chirurgii bariatrycznej. 
Videosurgery and other miniinvasive techiques, 2009. 4(Supl. 1): p. S31–S34.
10. Budzyński, A., et al., Polskie rekomendacje w zakresie chirurgii bariatrycznej 
i metabolicznej. Medycyna Praktyczna – Chirurgia, 2016. 6.
11. Kaska, Ł., et al., A prospective evaluation of the influence of three bariatric pro-
cedures on insulin resistance improvement. Should the extent of undiluted bile 
transit be considered a key postoperative factor altering glucose metabolism? 
Wideochirurgia i inne techniki małoinwazyjne/Videosurgery and Other Mi-
niinvasive Techniques, 2015. 10(2): p. 213-228.
12. Proczko-Markuszewska, M., et al., Early results of Roux-en-Y gastric by-pass 
on regulation of diabetes type 2 in patients with BMI above and below 35 kg/
m2. Pol Przegl Chir, 2011. 83(2): p. 81-6.
13. Janik, M.R., E. Stanowski, and K. Paśnik, Present status of bariatric surgery 
in Poland. Wideochirurgia i inne techniki małoinwazyjne/Videosurgery and 
Other Miniinvasive Techniques, 2016. 11(1): p. 22-25.
14. Saw, E.C., W. Ku, and S. Ramachandra, Laparoscopic resection of a splenic 
artery aneurysm. J Laparoendosc Surg, 1993. 3(2): p. 167-71.
15. Carr, S.C., et al., Current management of visceral artery aneurysms. Surgery, 
1996. 120(4): p. 627-33; discussion 633-4.
16. Arepally, A., et al., Treatment of splenic artery aneurysm with use of a stent-
-graft. J Vasc Interv Radiol, 2002. 13(6): p. 631-3.
17. Arca, M.J., et al., Splenic artery aneurysms: methods of laparoscopic repair. J 
Vasc Surg, 1999. 30(1): p. 184-8.
WWW.PPCH.PL48
 original article
18. Piffaretti, G., et al., Splenic artery aneurysms: postembolization syn-
drome and surgical complications. Am J Surg, 2007. 193(2): p. 166-70.
19. Gao, B.L., et al., Delayed coil migration from a small wide-necked aneu-
rysm after stent-assisted embolization: case report and literature review. 
Neuroradiology, 2006. 48(5): p. 333-7.
20. Saltzberg, S.S., et al., Is endovascular therapy the preferred treatment 
for all visceral artery aneurysms? Ann Vasc Surg, 2005. 19(4): p. 507-15.
21. Guillon, R., et al., Management of splenic artery aneurysms and false 
aneurysms with endovascular treatment in 12 patients. Cardiovasc In-
tervent Radiol, 2003. 26(3): p. 256-60.
22. Agrawal, G.A., P.T. Johnson, and E.K. Fishman, Splenic artery aneury-
sms and pseudoaneurysms: clinical distinctions and CT appearances. 
AJR Am J Roentgenol, 2007. 188(4): p. 992-9.
23. Yamamoto, S., et al., Transcatheter coil embolization of splenic artery 
aneurysm. Cardiovasc Intervent Radiol, 2008. 31(3): p. 527-34.
24. Kagaya, H., et al., Long-term results of endovascular treatment for sple-
nic artery aneurysms. Int Angiol, 2011. 30(4): p. 359-65.
25. Adams, T.D., et al., Long-term mortality after gastric bypass surgery. N 
Engl J Med, 2007. 357(8): p. 753-61.
26. Moriyama, H., et al., Laparoscopic approaches for splenic artery aneury-
sms. Minim Invasive Ther Allied Technol, 2012. 21(5): p. 362-5.
27. Trastek, V.F., P.C. Pairolero, and P.E. Bernatz, Splenic artery aneurysms. 
World J Surg, 1985. 9(3): p. 378-83.
28. Lakin, R.O., et al., The contemporary management of splenic artery aneu-
rysms. J Vasc Surg, 2011. 53(4): p. 958-64; discussion 965.
29. Mandal, S., P.M. Das, and A.K. Mandal, Caroli’s syndrome leading to 
splenic artery aneurysm: a rare presentation. Int J Surg Pathol, 2009. 
17(1): p. 78-80.
30. Largent, J.A., et al., Reduction in Framingham risk of cardiovascular di-
sease in obese patients undergoing laparoscopic adjustable gastric ban-
ding. Adv Ther, 2013. 30(7): p. 684-96.
31. International Task Force for Prevention of Coronary Heart Desease / 
International Atherosclerosis Society, Skala Framingham, in Zapobie-
ganie Chorobie   Niedokrwiennej Serca Poradnik Kieszonkowy. 2003, 
Verso s.c.: Szczecin. p. 22-26.
32. Hrynkiewicz-Szymańska, A., Diagnostyka choroby niedokrwiennej 
serca w grupie pacjentówz cukrzycą. Kardiologia na co Dzień, 2010. 
5: p. 45-47.
DOI:
Table of content:
Copyright:
Funding:
Competing interests:
Corresponding author:
Cite this article as:
Word count: 3100               Page count: 9          Tables: 3          Figures: 3          References: 32
10.5604/01.3001.0009.7176
http://ppch.pl/resources/html/articlesList?issueId=9609
Copyright © 2017 Fundacja Polski Przegląd Chirurgiczny. Published by Index Copernicus Sp. z o. o. 
All rights reserved.
The publication of this article was supported by the Faculty of Medicine, Jagiellonian University 
Medical College, Leading National Research Centre (KNOW) 2012–2017
The authors declare that they have no competing interests. 
The content of the journal „Polish Journal of Surgery” is circulated on the basis 
of the Open Access which means free and limitless access to scientific data.
This material is available under the Creative Commons - Attribution 4.0 GB. The full terms of this 
license are available on: http://creativecommons.org/licenses/by-nc-sa/4.0/legalcode
Piotr Major, II Katedra Chirurgii Ogólnej - Uniwersytet Jagielloński Collegium Medicum, Kraków, 
Polska; e-mail: majorpiotr@gmail.com 
Major P., Kowalczuk A., Wysocki M., Osadnik S., Pędziwiatr M., Głuszewska A., Pisarska M.,  Małczak 
P., Lasek A., Kisielewski M, Budzyński A.; Effects of bariatric surgery on cardiovascular risk factors 
among morbidly obese patients; Pol Przegl Chir 2017: 89 (1): 41-49

